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Abstract
Pyrrolopyrimidine containing natural products are widely distributed in Nature. The biosynthesis 
of the 7-deazapurine moiety that is common to all pyrrolopyrimidines entails multiple steps, one 
of which is a complex radical-mediated ring contraction reaction catalyzed by CDG synthase. 
Herein we review the biosynthetic pathways of deazapurines, focusing on the biochemical and 
structural insights into CDG synthase.
Introduction
Pyrrolopyrimidine functional groups, more commonly referred to as 7-deazapurines, are 
components of a large class of biological molecules that are found in all domains of life. To 
date, over 30 deazapurines have been isolated from diverse sources as diffusible metabolites 
produced by microorganisms in soil and marine environments or hypermodified bases 
incorporated into tRNA of nearly all organisms (see [1] for a recent review). The widespread 
distribution of deazapurines suggests that their biosynthetic pathways evolved early and 
have been maintained because they play significant roles, which remain to be established. 
Most were isolated on the basis of their herbicidal, antibacterial, antifungal, and 
antineoplastic activities, suggesting that this scaffold may be particularly suited for 
incorporation into therapeutic agents.
7-Cyano-7-deazaguanine, commonly referred to as toyocamycin, was the first of the 7-
deazapurines described in the literature [2] (Fig 1). The compound was found as a diffusible 
metabolite in the culture medium of Streptomyces toyocaensis and isolated on the basis of its 
anti-candida activity The deazapurine-containing hypermodified RNA base, queuosine, was 
first found in Escherichia coli but has since been shown to be present in Asp, Asn, His, and 
Tyr tRNA of nearly all organisms [3–5]. Early attempts at elucidating the biosynthetic 
pathways to these compounds utilized radioisotope tracers [6–8] (see Fig. 1 for summary). 
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Regardless of the metabolite, purines were found to be the starting material, and analysis of 
labeling patterns showed that the C-2 of the starting purine was retained whereas C-8 was 
not. The similarity between this distinctive labeling pattern to that observed for folic acid 
and riboflavin suggested that they may share common biosynthetic steps [9–13]. In addition, 
the observation that C-1’, C-2’, and C-3’ of the ribose in the proffered purine are 
incorporated into the deazapurine suggested unprecedented rearrangements [6].
Biosynthesis of Deazapurines
The biosynthetic pathway to the 7-deazapurine core was elucidated by identification of the 
cluster of genes involved in the biosynthesis of sangivamycin and toyocamycin in 
Streptomyces rimosus [14]. Since the genes for biosynthesis of secondary metabolites in 
Streptomyces tend to be clustered, the search for the biosynthetic pathway focused on 
identification of a nitrile hydratase activity, which had been shown to convert toyocamycin 
to sangivamycin. The toyocamycin nitrile hydratase (TNHase) protein was purified and the 
N-terminal sequences of this heterotrimeric protein were used to identify the gene cluster in 
a cosmid library of S. rimosus. Sequencing a ~13 kbp region surrounding the TNHase genes 
led to identification of 13 open reading frames which, based on sequence comparisons, 
appeared to encode the biosynthetic pathway. Independently, four genes of unknown 
function were shown to be required for the biosynthesis of queuosine in Acenitobacter 
calcoaceticus [15].
Bioinformatic analysis of the orfs in the toyocamycin/sangivamycin gene cluster led to two 
key insights. First, as had been suspected from the radiotracer experiments discussed above, 
the cluster revealed a link between folic acid and deazapurine biosynthetic pathways. 
Specifically, a GTP cyclohydrolase I (GCH I) homolog was found in the cluster. GCH I 
catalyzes the conversion of GTP to 7,8-dihydroneopterin triphosphate (H2NTP) in the first 
step of folic acid biosynthesis, and entails loss of C-8 and retention of the C-2 of GTP. 
Second, three of the orfs in the cluster are homologous to proteins encoded by genes deemed 
essential for the biosynthesis of queuosine in A. calcoaceticus, suggesting that Nature 
employs similar paradigms for biosynthesis of all pyrrolopyrimidines.
The key steps in the biosynthetic pathway were elucidated by in vitro reconstitution of the 
enzymatic transformations [14,16,17]. The biosynthetic pathway to deazapurines can be 
divided into two phases. In the first, 7-carboxy-7-deazaguanine (CDG), which is likely the 
common intermediate to all deazapurines, is formed from GTP (Fig. 2). The second phase in 
the biosynthetic pathway is different for each deazapurine and involves steps to tailor the 
CDG to the desired metabolite.
The first phase of the biosynthetic pathway entails conversion of GTP to CDG by three 
successive enzymatic transformations [16,17]. The first reaction is catalyzed by GCH I, 
which converts GTP to H2NTP [14,18]. This step is common to the biosynthesis of folic 
acid, which was expected on the basis of the similarities between the radiotracer 
experiments [6,7]. Examination of genome databases suggests that the GCH I homolog that 
is involved in the biosynthesis of folic acid also serves to provide the H2NTP required for 
the biosynthesis of deazapurines.
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In the second step H2NTP undergoes sidechain cleavage catalyzed by 6-
carboxytetrahydropterin (CPH4) synthase [17]. CPH4 synthase is homologous to the 6-
pyruvoyltetrahydropterin synthase, which catalyzes the second step in the mammalian 
pathway to biopterin involving conversion of H2NTP to 6-pyruvoyltetrahydropterin (PPH4) 
[19]. Interestingly, biochemical studies have shown that the CPH4 synthase involved in the 
biosynthesis of 7-deazapurines also accepts PPH4 and sepiapterin as substrates, but produces 
CPH4 as the only product [17]. Structural studies suggest that despite significant structural 
similarities, changing the identities of two amino acids in the active site of CPH4 synthase 
relative to the mammalian PTPS may explain the differing fates of H2NTP [20].
The third and key ring contraction step to form the pyrrolopyrimidine core is catalyzed by 7-
carboxy-7-deazaguanine (CDG) synthase [16]. CDG synthase catalyzes a complex radical-
mediated ring contraction reaction to convert CPH4 to CDG. Substantial biochemical and 
structural evidence is now available to illuminate the mechanism of this fascinating 
transformation [16,21,22].
The second phase of the biosynthetic pathway entails tailoring CDG to the desired 
secondary metabolite.
The biosynthetic pathways diverge in the second phase, which involves tailoring CDG. Five 
steps are involved in tailoring CDG to the hypermodified tRNA base, queuosine (Fig. 3A). 
In the first, CDG is converted to preQ0 by the action of preQ0 synthetase, which catalyzes 
the ATP-dependent conversion of the carboxyl moiety of the substrate to a cyano group 
[16,23]. The ATP is used to activate CDG as an adenylate which, in the presence of 
ammonia, forms a 7-amido-7-deazaguanine intermediate (ADG) [23]. ADG is subsequently 
converted to preQ0 in an ATP-dependent manner [23]. In the second step, preQ0 is reduced 
by an NADPH-dependent reductase to generate preQ1 [24], which is exchanged for guanine 
in the wobble position of tRNA in the third step [25,26]. This is an unusual exchange 
reaction that involves formation of a covalent adduct between the ribose and the enzyme, 
followed by attack with the preQ1 base [27– 29]. The fourth step is modification of preQ1-
tRNA with a cyclopentanediol epoxide moiety derived from S-adenosyl-L-methionine 
(SAM) to form epoxyqueuosine (oQ) [30,31]. In the final step the epoxide moiety is reduced 
by oQ reductase to form queuosine (Q). oQ reductase was identified recently by searching 
an E. coli knockout library for a strain that was devoid of Q in cellular RNA [32]. Despite 
their vastly different substrates, oQ reductase is homologous to enzymes that carry out 
reductive dehalogenation [33,34]. The enzyme has been shown to contain two 4Fe-4S 
clusters and a cobalamin cofactor, which are all required for activity [35].
With the exception of sangivamycin and toyocamycin (Fig. 3B), the steps involved in 
tailoring CDG to the secondary metabolites containing 7-deazapurines, have not been 
determined. The biosynthetic gene cluster for production of sangivamycin and toyocamycin, 
in addition to a preQ0 synthetase homolog, encodes several nucleotide biosynthesis/salvage 
enzymes, which are hypothesized to convert preQ0 to toyocamycin [14]. The conversion of 
toyocamycin to sangivamycin is catalyzed by a cobalt-type nitrile hydratase enzyme [14,36].
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The remainder of this review will focus on the current understanding of CDG synthase, 
which catalyzes the key complex radical-mediated ring contraction reaction in the 
biosynthetic pathway.
Radical-mediated transformation catalyzed by CDG synthase
CDG synthase is a member of the radical SAM (RS) superfamily [37]. This superfamily was 
defined on the basis of the sequence motif, CxxxCxxC, which provides thiolato ligands to 
bind three iron atoms of a 4Fe-4S cluster. The fourth iron coordinates the amino and 
carboxylate moieties of SAM [38]. The cluster in the +1 oxidation state reductively cleaves 
SAM to generate 5’-deoxyadenosyl radical (dAdo•), which is subsequently utilized for 
radical-mediated transformations (Fig. 4A). In most of these enzymes, dAdoabstracts a 
hydrogen atom to initiate catalysis. It is estimated that >113,000 radical SAM homologs are 
encoded in bacterial genomes [39].
Interestingly, CDG synthases display important exceptions to the CxxxCxxC consensus 
motif, whereby homologs with both the canonical and non-canonical (Cx14Cx2C) spacing of 
Cys residues have been identified [16,22]. A structure of the canonical homolog is not 
known, but it is expected to bind its FeS cluster as has been observed in all other members 
of the superfamily [40]. The X-ray crystal structure of the non-canonical homolog from 
Burkholderia multivorans shows that the 11-amino acid insertion in the CxxxCxxC motif 
forms a 310-helix above the FeS cluster [22]. Also, this non-canonical homolog does not 
display the typical partial (β/α)6 barrel fold and instead comprises a (β6/α3) barrel.
Activation of RS enzymes requires reduction of the catalytic cluster to the +1 oxidation 
state. In vitro, low potential reductants such as dithionite are commonly used to activate the 
protein [41]. However, in vivo it is thought that the electrons are supplied by NADPH via a 
flavodoxin (Fld)/flavodoxin reductase (Fpr) system (see Fig. 4A). As mentioned above, the 
reduced Fe-S cluster catalyzes the reductive cleavage of SAM to generate the highly reactive 
oxidant dAdo•, which initiates the catalytic cycle by abstracting a H-atom from the substrate 
(Fig. 4B). In a subset of radical SAM enzymes, reductive cleavage of SAM occurs 
stoichiometrically, whereas in others, SAM plays a catalytic role. CDG synthase utilizes 
SAM catalytically and at least 10 turnovers can be achieved under optimal conditions with 
each SAM [21]. However, in CDG synthase and nearly all other radical SAM enzymes, 
there is an abortive cleavage reaction that occurs when SAM is reductively cleaved and the 
dAdois quenched by H-atom transfer from a different site. In CDG synthase, the rate of the 
abortive cleavage reaction with the Bacillus subtilis protein is below the limit of detection 
when NADPH serves reducing equivalents via FldA/Fpr. In the absence of the complete 
biological reducing system, the rate is low (~0.3 min−1) and not dependent on the presence 
or absence of FldA [42].
Although Fld/Fpr are hypothesized to be involved in the activation of RS enzymes and 
routinely used in vitro to activate RS enzyme, little is known about this interaction at the 
molecular level. Further confounding this, two flavodoxin homologs are encoded in the 
genomes of many organisms and only one of the two E. coli Fld homolog, FldA, has been 
used in RS enzymology to date. A recent kinetic study of the reductive activation of B. 
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subtilis CDG synthase revealed that one of the two flavodoxin homologs encoded YkuN, is 
10-fold more efficient in supporting activation of the enzyme (Fig. 5A) [42]. By 
comparison, the E. coli Fld homolog was shown to be less efficient in maintaining B. subtilis 
CDG synthase activity. In these experiments, efficiency is measured as the ratio of maximal 
activity obtained at saturating Fld (kcat) and concentration of Fld that afforded half maximal 
activation (KFld). Similar results were obtained regardless of whether Fld, which was 
reduced with dithionite, or with NADPH/Fpr (see Fig. 5B), was used in the assays with B. 
subtilis CDG synthase. In all cases, Fld was a better mediator than dithionite, suggesting that 
the differences are likely localized to the Fld•CDG synthase complex. There are many 
caveats in the interpretation of these results, including the fact that the in vivo concentrations 
of the various Fld homologs are not known. As the differences in efficiency of activation of 
CDG synthase by chemical and biological reductants highlights, a better understanding of 
reductive activation may be necessary if one is to be able to elucidate the reactions catalyzed 
by this large and growing superfamily of enzymes.
Catalytic Mechanism of CDG synthase
The mechanism by which the 6-membered ring of CPH4 undergoes ring contraction has 
been examined by isotope labeling experiments (Fig. 6) [21]. Upon reductive cleavage, 
CDG synthase would be expected to carry out H-atom abstraction from C6 or C7 of the 
substrate. Studies with C-6 and C-7 deuterated isotopologs of CPH4 substrates have 
demonstrated that the reaction is initiated by H-atom abstraction at C-6. Incubation of CDG 
synthase with isotopologs of CPH4 where deuterium is located at the 7-proS or 7-proR 
positions of the substrate, does not lead to labeling of dAdo. In the X-ray crystal structure of 
CPH4 bound to CDG synthase, the 5′-position of the cofactor is within 3.4 Å of the C-6 of 
the substrate, poised for H-atom abstraction upon reductive cleavage of the cofactor [22] 
(see Fig. 6 insert).
Abstraction of a H-atom from C-6 of CPH4 leads to an initial radical intermediate, which 
would be stabilized by delocalization. Although there is no structural or spectroscopic 
evidence for this intermediate, the structure of the 6-carboxypterin, which is a substrate 
analog, provides an indication of localization as it mimics the planar arrangement at C-6 
[22] (see Fig. 6 insert). The mechanism by which this intermediate undergoes ring 
contraction is not known, but there are two reasonable possibilities. One may envision that 
the reaction would proceed via an aziridine-like intermediate, where the unpaired spin 
density would be stabilized by delocalization. Alternatively, the rearrangement may proceed 
through a ring opening followed by closure by 5-exo-trig to generate the 5-membered ring. 
Computational studies favor the aziridine-like intermediate in the rearrangement [43]. In 
both cases, the resulting radical would be quenched by H-atom abstraction of an H-atom 
from the dAdo to form the gem-aminocarboxylate intermediate and allow regeneration of 
the cofactor. Although a structure of this complex is not available, its position can be 
modeled on the basis of the site of binding of CDG (see Fig. 6 insert).
The conversion of the gem-aminocarboxylate intermediate to CDG requires elimination of 
ammonia. Studies with the isotopologs of CPH4 have shown that when deuterated at C-7, 
the label at the 7-proR position is selectively retained in the CDG product [21]. This 
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observation suggests that the elimination of ammonia and aromatization to form CDG occur 
on the enzyme. Computational studies suggest that elimination of the ammonia to form the 
CDG product is the rate-determining step [43]. It is possible, for example, that the exocyclic 
amino group of the pyrimidine ring could be used to eliminate ammonia. Such an 
intermediate would have an acidic proton at C-7 that can be abstracted by an appropriate 
base to generate the product. Indeed, in the structure of the product complex, a Glu side 
chain is within distance from the appropriate face of the substrate for abstraction (see Fig. 6 
insert).
Superposition of the structures of the substrate, intermediate analog, and product complexes 
of CDG highlight the fact that there is minimal movement in the active site of the protein as 
the substrate undergoes activation and conversion to product (see Fig. 7 for overlay). This 
design principle is an emerging theme in RS enzymes because the highly reactive 
intermediates can do side-reactions if they are not controlled [44,45]. One may quip that 
while technically these enzymes produce “free radical intermediates”, there is nothing “free” 
about the intermediates!
A curious observation that was made in the course of the biochemical studies of CDG 
synthase was that that in addition to an FeS cluster, CDG synthase also requires a Mg2+ for 
catalytic activity [21]. In addition to revealing details of binding of the substrate, the 
structures of the B. multivorans homolog also provide insights into the role of the required 
magnesium divalent cation [22]. Close examination of the binding interactions between 
CPH4 and the enzyme shows that while the substrate makes several contacts with the 
enzyme, the magnesium divalent cation “templates” the substrate-binding site (Fig. 8). The 
Mg2+ interacts with the carboxylate oxygen as well as the carbonyl oxygen in the pyrimidine 
ring. By contrast, the only contact between the divalent cation and the enzyme is an 
interaction with the hydroxyl sidechain of a threonine residue. It is worth noting that the 
substrate makes nearly as many interactions with the bound divalent cation as with protein 
side chains, suggesting that the divalent cation serves as a key binding determinant. A role 
for the Mg2+ beyond positioning of the substrate in the active site is not known. It has been 
suggested that it may serve as a Lewis acid to facilitate the deamination of the substrate.
Future directions
The radical-mediated ring contraction catalyzed by CDG synthase is complex and affords 
the ideal platform to explore the structural and biochemical details of reductive activation 
and catalysis. CDG synthase is only one of several novel enzymes that were discovered in 
the course of studies of biosynthesis of 7-deazapurines, and future studies on the 
biosynthesis of the remaining pyrrolopyrimidines may lead to discovery of additional novel 
transformations.
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Highlights
• Pyrrolopyrimidines are widely distributed in Nature.
• Biosynthesis of 7-deazapurine core of all pyrrolopyrimidines entails a radical-
mediated ring contraction
• CDG synthase catalyzes a complex radical-mediated ring contraction
• CDG synthase is a member of the radical SAM superfamily
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Figure 1. 
Labeling patterns observed in the biosynthesis of folic acid and deazapurines. In both cases, 
C-2 (red sphere) of the starting purine is retained but C-8 (grey sphere) is lost. In addition, 
C-1’, C-2’, and C-3’ (blue spheres) of the proffered purine ribose become incorporated into 
the final product.
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Figure 2. 
Core steps in the biosynthesis of 7-deazapurines are catalyzed by the successive actions of 
three enzymes.
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Figure 3. 
Tailoring steps from CDG to (A) the hypermodified tRNA base queuosine and (B) the 
secondary metabolites toyocamycin and sangivamycin.
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Figure 4. 
Activation of RS enzymes requires reduction of the [4Fe-4S] cluster to the +1 oxidation 
state. In vivo, NADPH is thought to supply the necessary reducing equivalents via Fpr/Fld 
(A). Once reduced, the RS cluster catalyzes the reductive cleavage of SAM to generate a 
dAdo•, which initiates catalysis by H-atom abstraction from the substrate (B).
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Figure 5. 
Reductive activation of B. subtilis CDG synthase with Fld homologs from E. coli and B. 
subtilis. Both the biological reducing system NADPH/Fld/Fpr (A) and dithionite/Fld (B) are 
able to activate CDG synthase. Of the Fld homologs, YkuN is able to maintain activity of 
CDG synthase at significantly lower concentrations than YkuP or Fld.
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Figure 6. 
Mechanism of CDG synthase. Radical-mediated ring contraction is initiated by H-atom 
abstraction at C-6 (hydrogen in light blue) of the substrate, and product is formed by 
stereoselective proton abstraction from a putative gem-aminocarboxylate intermediate. 
Lower inserts show active sites from the structures of CPH4 (PDB:4NJI), 6-CP (PDB:
4NJG), and CDG (PDB: 4NJK) bound near the [4Fe-4S] of CDG synthase. The structure 
below the gem-aminocarboxylate intermediate is a model based on how CDG binds to CDG 
synthase. Glu 116 is also shown in this panel. Colors for the structures: Fe in rust, S in 
yellow, C in green, N in blue, O in red, and modeled H in white. The 7-proS and 7-proR 
hydrogens are shown in black and red spheres, respectively.
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Figure 7. 
CPH4, CDG and 6-CP are all bound in the same manner with respect to the SAM-bound 
[4Fe-4S] cluster in the active site of CDG synthase. Color of the FeS cluster and SAM are as 
described as in Fig. 6.
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Figure 8. 
Magnesium divalent cation (orange sphere) serves as a major binding determinant for CPH4 
in the active site of CDG synthase. The substrate makes three contacts to the Mg2+. A Thr 
sidechain from the protein is also a ligand. The C-terminal carboxylate and Arg27 are also 
involved in binding the substrate. Colors are as described in Fig. 6 with the hydrogen that is 
abstracted (white) modeled into the structure.
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